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he breast cancer susceptibility gene 
 
BRCA1
 
 encodes
a protein that has been implicated in multiple nuclear
functions, including transcription and DNA repair. The
multifunctional nature of BRCA1 has raised the possibility
that the polypeptide may regulate various nuclear processes
via a common underlying mechanism such as chromatin
remodeling. However, to date, no direct evidence exists in
mammalian cells for BRCA1-mediated changes in either
local or large-scale chromatin structure. Here we show that
targeting BRCA1 to an ampliﬁed, lac operator–containing
chromosome region in the mammalian genome results in
large-scale chromatin decondensation. This unfolding activity
is independently conferred by three subdomains within the
transactivation domain of BRCA1, namely activation domain
1, and the two BRCA1 COOH terminus (BRCT) repeats. In
addition, we demonstrate a similar chromatin unfolding
T
 
activity associated with the transactivation domains of E2F1
and tumor suppressor p53. However, unlike E2F1 and p53,
BRCT-mediated chromatin unfolding is not accompanied
by histone hyperacetylation. Cancer-predisposing mutations
of 
 
BRCA1
 
 display an allele-speciﬁc effect on chromatin
unfolding: 5
 
 
 
 mutations that result in gross truncation of the
protein abolish the chromatin unfolding activity, whereas
those in the 3
 
 
 
 region of the gene markedly enhance this
activity. A novel cofactor of BRCA1 (COBRA1) is recruited
to the chromosome site by the ﬁrst BRCT repeat of BRCA1,
and is itself sufﬁcient to induce chromatin unfolding.
BRCA1 mutations that enhance chromatin unfolding also
increase its afﬁnity for, and recruitment of, COBRA1. These
results indicate that reorganization of higher levels of
chromatin structure is an important regulated step in
BRCA1-mediated nuclear functions.
 
Introduction
 
Germ line mutations in breast cancer susceptibility gene 1
 
(
 
BRCA1
 
)* confer elevated risks in the development of familial
breast and ovarian cancers (Rahman and Stratton, 1998).
 
BRCA1
 
 encodes a 1,863–amino acid protein with a highly
conserved ring finger motif (RING) at the NH
 
2 
 
terminus,
and two BRCA1 COOH terminus (BRCT) repeats at the
extreme COOH terminus. Whereas most disease-associated
mutations of BRCA1 are predicted to result in gross truncation
of the protein, 5–10% of the cancer-predisposing mutations
cause single amino acid substitutions, many of which are
located in the RING domain or BRCT repeats.
Intense research in the past several years has implicated
BRCA1 in the regulation of multiple nuclear processes,
including DNA repair and transcription (Zhang et al.,
1998b; Scully and Livingston, 2000). For example,
BRCA1-deficient mouse and human cells are hypersensitive to
ionizing radiation due to defects in transcription-coupled
repair of oxidative DNA damage, as well as double-strand
break-induced homologous recombination (Gowen et al.,
1998; Abbott et al., 1999; Moynahan et al., 1999; Scully et
al., 1999; Xu et al., 1999). In addition, BRCA1 associates
with several repair and recombination proteins such as
RAD51 (Scully et al., 1997b), RAD50/MRE11/NBS1
(Zhong et al., 1999; Wang et al., 2000), and MSH2/MSH6
(Wang et al., 2000). BRCA1 also interacts with and is
phosphorylated by protein kinases that are key players in the
damage checkpoint control, including ATM, ATR, and
CHK2 (Cortez et al., 1999; Lee et al., 2000; Tibbetts et al.,
2000). Lastly, it has been shown recently that BRCA1
preferentially binds to branched DNA structures (Paull et
al., 2001).
In addition to its potential role in DNA repair, BRCA1
has also been implicated in regulation of transcription
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(Monteiro, 2000; Scully and Livingston, 2000). When teth-
ered to a transcriptional promoter via a heterologous DNA
binding domain, the COOH-terminal 304–amino acid (aa)
region including the BRCT repeats (Fig. 1 B, AD2, amino
acids 1560–1863) can act as a transactivation domain
(Chapman and Verma, 1996; Monteiro et al., 1996). More
recent work has revealed a second transactivation domain of
BRCA1 that resides upstream of the BRCT repeats (Hu et
al., 2000) (Fig. 1 B, AD1, aa 1293–1559). The two activa-
tion domains (ADs), AD1 and AD2, can cooperatively acti-
vate transcription in many cell lines tested (Hu et al., 2000).
Consistent with its potential role in transcriptional regula-
tion, the BRCA1 polypeptide is associated with the RNA
polymerase II holoenzyme via RNA helicase A (Scully et al.,
1997a; Neish et al., 1998). Furthermore, BRCA1 interacts
with a number of site-specific transcription factors and mod-
ulates their actions in gene activation (Somasundaram et al.,
1997; Ouchi et al., 1998, 2000; Zhang et al., 1998a; Fan et
al., 1999; Houvras et al., 2000; Zheng et al., 2000).
The multifunctional nature of BRCA1 has raised the pos-
sibility that the protein may employ a common mechanism,
such as chromatin remodeling, to regulate various chro-
mosomal events. Indeed, the COOH-terminal region of
BRCA1 (AD2), which is required for BRCA1 functions in
both DNA repair and transcription (Monteiro, 2000; Scully
and Livingston, 2000), can induce changes in nucleosome
structure when tethered to chromosomal DNA in 
 
Saccharo-
myces cerevisiae
 
 (Hu et al., 1999). Furthermore, BRCA1 is
associated with histone modifying enzymes (p300 and
HDAC) (Neish et al., 1998; Yarden and Brody, 1999; Pao
et al., 2000) and an ATP-dependent chromatin remodeling
machine (hSNF/SWI) (Bochar et al., 2000). The fact that
many cancer-predisposing mutations reduce BRCA1’s affin-
ity for these chromatin-modifying proteins suggests that
chromatin remodeling may be an important aspect of
BRCA1-mediated tumor suppression. However, currently
there is no direct evidence in mammalian cells for BRCA1-
mediated changes in chromatin structure. This is in part due
to the lack of convenient assays for directly monitoring chro-
matin remodeling at different levels of chromatin structure
in mammalian cells.
A lac repressor–based system has allowed direct visualiza-
tion of large-scale chromatin dynamics in mammalian cells
(Belmont, 2001). In this system, multiple copies of the lac
operator were engineered into the genome of CHO cells, and
together with the surrounding genomic sequences, were am-
plified to produce a 90-Mb heterochromatic region. By fus-
ing lac repressor with the acidic AD (AAD) of the strong
viral transcription factor VP16 and tethering the fusion
protein to the heterochromatic chromosome region, this sys-
tem was used to demonstrate AAD-induced large-scale chro-
matin decondensation (Tumbar et al., 1999). This large-
scale chromatin uncoiling occurred even when RNA pol
II–dependent transcription was blocked, suggesting that it
was induced through transacting factors recruited by the
VP16 AAD, rather than the result of transcription per se.
Conceptually, the transacting factors producing this higher
order chromatin decondensation could be one of the known
chromatin-modifying complexes that modify local nucleo-
some structure (Peterson and Logie, 2000). Alternatively, AAD-
induced chromatin unfolding could involve novel factors act-
ing primarily at the higher levels of chromatin organization.
Although artificial, this lac repressor–tethering system
provides a very quick, and therefore powerful, assay to test
the possible role of specific proteins in chromatin remodel-
ing and to dissect the protein domains required for the ob-
served large-scale chromatin decondensation. Using this lac
repressor–tethering assay, we demonstrate here that BRCA1
induces large-scale chromatin decondensation. We also
identify three small subdomains within the transactivation
domain of BRCA1 that are capable of independently confer-
ring chromatin unfolding. In addition, cancer-predisposing
mutations of BRCA1 display allele-specific effects on the
chromatin unfolding activity. Finally, we isolate a novel co-
factor of BRCA1 (COBRA1) that binds to one of the chro-
matin-unfolding domains of BRCA1, and by itself induces
large-scale chromatin decondensation. Our results suggest
that BRCA1-mediated decondensation of higher levels of
chromatin structure may represent a new physiological regu-
latory pathway related to BRCA1 function. The approach
used in the current study also provides a new methodology
for identifying novel BRCA1-interacting proteins involved
in this regulatory pathway.
 
Results
 
BRCA1-mediated large-scale chromatin 
decondensation in mammalian cells
 
To assess the impact of BRCA1 on large-scale chromatin
structure in mammalian cells, we made use of a CHO cell
line, AO3_1, in which multiple copies of the lac operator
were engineered to produce a 90-Mb heterochromatic re-
gion of the genome (Robinett et al., 1996; Li et al., 1998;
Tumbar et al., 1999). The molecular organization of this re-
gion consists of 
 
 
 
400-kb repeats of the 14-kb vector trans-
gene that contains the lac operator repeat and dihydrofolate
reductase selectable marker. The repeats are separated on av-
erage by 
 
 
 
1,000 kb of unknown coamplified genomic
DNA. Because other cell clones derived from the same selec-
tion procedure contain more open, gene-amplified chromo-
some regions with comparable or greater content of the vec-
tor DNA, the heterochromatic appearance of the A03_1
chromosome region is assumed to be due to properties of the
coamplified genomic DNA. In vivo binding of lac repressor
or its GFP derivatives to this chromosomal site allows direct
visualization of large-scale chromatin dynamics without al-
tering the original chromosome structure.
Consistent with previous findings, lac repressor–express-
ing cells stained with the corresponding antibody exhibited a
compact nuclear dot (Fig. 1 A, a). In contrast, expression of
lac repressor fused with the full-length BRCA1 induced an
irregularly shaped subnuclear structure in 14% of trans-
fected cells (Fig. 1 A, b). Such a staining pattern was not
present in any of the cells expressing lac repressor alone.
These results suggest that BRCA1, or a BRCA1-associated
protein, can induce large-scale chromatin restructuring. The
magnitude of this opening was lower than observed for the
VP16 AAD, and was present in a lower percentage of cells
(14 vs. 60% for VP16 AAD) (Tumbar et al., 1999 and see
Fig. 2). The lack of a response in 100% of cells, even for the 
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VP16 AAD, is not yet understood. It may represent a com-
bination of several factors, including cell cycle–dependent
expression as well as the nature of the qualitative assay em-
ployed. Transgene arrays have been shown to display coordi-
nated gene silencing effects that are accompanied by cooper-
ative changes in chromatin structure across the entire array
(Pikaart et al., 1998). These changes in gene expression and
chromatin structure show a variegating phenotype that is
clonally inherited. Therefore, it is possible that the large-
scale chromatin decondensation induced by a transcriptional
activator in the lac system may also display cooperative and
variegating responses.
Deletion analysis showed that chromatin-unfolding activ-
ity was conferred by the last 570 aa of BRCA1 (Fig. 1 B, aa
1293–1863). This region of BRCA1, previously designated
AD (Hu et al., 1999), consists of two subdomains that act
synergistically to stimulate transcription (Fig. 1 B, AD1, aa
1293–1559, and AD2, aa 1560–1863). As illustrated in Fig.
1 B, AD2 contains the two BRCT repeats, BRCT1 and
BRCT2. Further domain mapping indicated that AD1,
BRCT1, and BRCT2 could independently induce large-
scale chromatin unfolding (Fig. 1 A, c, e, and f, and B). It is
of note that AD1 often leads to a ball-shaped structure with
smooth edges, whereas BRCT1 and BRCT2 tend to give
rise to more extended, fiber-like structures with irregular
shapes (Fig. 1 A, compare c with e and f). The degree of un-
 
folding by BRCT1 and BRCT2 approached that observed
with VP16, with 
 
 
 
60% of cells showing this response,
whereas the AD1 subdomain showed intermediate unfold-
ing. Interestingly, both the magnitude of this unfolding and
the percentage of cells showing unfolding using these subdo-
mains was significantly higher than observed using the full-
length BRCA1 fusion protein (Fig. 1 B). Furthermore,
AD2, which includes both the BRCT1 and BRCT2 repeats,
failed to cause obvious decondensation of high-order chro-
matin structure (Fig. 1 A, compare d with e and f). As ex-
plained below, we interpret this as an indication of a nega-
tively regulated chromatin unfolding activity associated with
the full-length BRCA1 and AD2 region.
Further dissection of the BRCT1 domain shows that the
50-aa COOH-terminal half of BRCT1 is sufficient for induc-
ing maximal chromatin unfolding (Fig. 1 B, BRCT1C). In
contrast, the NH
 
2
 
-terminal half of BRCT1 (BRCT1N) with
a comparable size to BRCT1C, fails to mediate any chroma-
tin decondensation. Furthermore, none of the BRCA1 frag-
ments upstream of AD displayed any activity in chromatin
unfolding (Fig. 1 B, 1–324, 260–554, and 554–1293), al-
though they were expressed at similar levels as the chromatin-
unfolding domains (unpublished data and see Fig. 5 B). Pre-
vious studies have shown that these regions upstream of AD
are responsible for BRCA1 interactions with various proteins
or protein complexes. For example, the NH
 
2
 
-terminal region
Figure 1. BRCA1 induces large-scale chromatin 
decondensation. (A) The AO3_1 CHO cell line 
was transiently transfected with expression vectors 
for the following proteins: lac repressor (a),
lac–BRCA1(b), lac–AD1(c), lac– AD2(d),
lac–BRCT1(e), and lac–BRCT2(f). A polyclonal 
anti–lac repressor antibody and a Cy3-conjugated 
secondary anti–rabbit IgG were used for
immunostaining. Nuclei were visualized by DNA 
staining with DAPI. (B) The ability of various 
BRCA1 fragments to unfold chromatin was
measured by the percentage of transfected cells 
that displayed enlarged lac staining and the degree 
of unfolding. Over 100 transfected cells were
surveyed for each construct. Single, double, and 
triple plus signs indicate various degrees of
chromatin unfolding, as exemplified by images for 
lac–BRCA1 ( ), lac–AD1 (  ), and lac–BRCT1 
(   ). Also shown are schematic diagrams and 
amino acid coordinates for various BRCA1
fragments. 
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of BRCA1 binds BARD1 (Wu et al., 1996), whereas the cen-
tral region of the protein mediates BRCA1 interactions with
hSNF/SWI (Bochar et al., 2000), RAD50/MRE11/NBS1
(Zhong et al., 1999), and RAD51 (Scully et al., 1997b). The
inability of these regions to induce large-scale chromatin de-
condensation argues that chromatin unfolding is not simply
due to recruitment of any large proteins or protein complexes
to the lac binding sites. Rather, the chromatin unfolding ac-
tivity is conferred by three specific subdomains in the transac-
tivation domain of BRCA1, suggesting that chromatin
decondensation is related to BRCA1 functions in transcrip-
tional regulation and DNA repair.
 
Distinction between BRCT and other
well-characterized transactivation domains in
large-scale chromatin unfolding
 
A previous study has shown that VP16-induced chromatin
unfolding is accompanied by recruitment of histone acetyl-
transferases and local histone hyperacetylation, a property
frequently observed for transcriptionally active or competent
chromatin (Tumbar et al., 1999) (Fig. 2 A, m–o). Here we
extended the previous work by examining the transactiva-
tion domains of two cellular transcription factors, E2F1 and
p53. Like lac-VP16, lac-E2F1 and lac-p53 also induced sig-
nificant chromatin unfolding in 60 and 45% of transfected
cells, respectively (Fig. 2 A, g and j). Furthermore, the lac-
E2F1– and lac-p53–unfolded chromatin regions were en-
riched with hyperacetylated histone H3 and H4 (Fig. 2 A,
g–i and j–l, and unpublished data). Thus, all three well-
characterized transactivation domains (VP16, E2F1, and
p53) can simultaneously induce large-scale chromatin un-
folding and histone hyperacetylation. However, it remains
unknown whether the observed histone hyperacetylation is
causally related to chromatin unfolding.
The extent of chromatin decondensation induced by a sin-
gle BRCT repeat is comparable to that exhibited by these po-
tent transcriptional ADs (Fig. 2 A, compare a and d with g, j,
and m). However, no obvious histone H3 or H4 hyperacety-
lation was detected in the BRCT1- or BRCT2-unfolded
chromatin regions (Fig. 2 A, a–c and d–f), suggesting that
BRCT-mediated chromatin unfolding is a separable event
from histone acetylation. Although both BRCT repeats are
required for AD2-mediated transcriptional activation, a sin-
gle repeat does not serve as a strong AD (Chapman and
Verma, 1996; Monteiro et al., 1996) (unpublished data).
Figure 2. Comparison of chromatin unfolding by 
various lac fusion proteins. (A) Absence of histone 
hyperacetylation associated with BRCT-mediated 
chromatin unfolding. AO3_1 cells were trans-
fected with the expression vectors for lac fused 
with BRCT1 (a–c), BRCT2 (d–f), E2F1 (g–i), p53
(j–l), or VP16 (m–o). The lac (green), acetylated
histone H3 (red), and the merged images were
captured by confocal immunofluorescence
microscopy. (B) Association of lac–BRCA1 with 
phosphorylated H2AX. AO3_1 cells were
transfected with the lac–BRCA1 expression vector. 
Cells were double stained with the mouse anti-lac 
antibody and a rabbit anti– -H2AX antibody (1:100 
dilution; Upstate Biotechnology). 
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Therefore, chromatin unfolding by BRCT may be a neces-
sary, but not sufficient step, in transcriptional activation.
In addition to acetylation, histones are subject to other
posttranslational modifications under various physiologi-
cal conditions. Of particular interest, phosphorylation of
H2AX, a histone H2A variant, at serine 139 (
 
 
 
-H2AX) is
rapidly stimulated following ionizing radiation (Rogakou et
al., 1999). Before irradiation, a subset of 
 
 
 
-H2AX nuclear
foci colocalize with BRCA1 foci (Paull et al., 2000). After
DNA damage, the number of both 
 
 
 
-H2AX and BRCA1
nuclear foci increases significantly; furthermore, the major-
ity of BRCA1 foci overlapped 
 
 
 
-H2AX foci (Paull et al.,
2000). These observations most likely reflect localized re-
cruitment of the putative H2AX kinase and phosphorylation
of H2AX-containing nucleosomes that are already present at
these sites, rather than recruitment of new H2AX protein.
Using an antibody that specifically recognizes the phos-
phorylated form of H2AX (
 
 
 
H2AX), we detected colocal-
ization of the endogenous 
 
 
 
-H2AX with the full-length
BRCA1 fusion protein in a sub-population (15%) of the
 
lac–BRCA1-transfected cells (Fig. 2 B, a–c). In contrast, lac-
VP16 did not display any colocalization with 
 
 
 
-H2AX (Fig.
2 B, d–f), nor did lac-BRCT1 or lac-BRCT2 (unpublished
data). It is not clear whether phosphorylation of H2AX is
causally linked to BRCA1-mediated chromatin unfolding, as
 
 
 
-H2AX colocalization is also observed in lac–BRCA1-
expressing cells that do not display chromatin decondensa-
tion. Consistent with previous reports (Rogakou et al.,
1999; Paull et al., 2000), ionizing radiation significantly in-
creased the number and overall intensity of 
 
 
 
-H2AX foci
(unpublished data). However, the strong 
 
 
 
-H2AX signal
over the entire nucleus made it difficult to examine the effect
of DNA damage on the colocalization between 
 
 
 
-H2AX
and lac-BRCA1 at the lac binding sites.
Work by Paull et al. (2000) has shown that H2AX at the
damaged sites is rapidly phosphorylated after ionizing radia-
tion, which is followed later by colocalization of BRCA1
and other repair proteins (Paull et al., 2000). It is possible
that the putative kinase(s) responsible for H2AX phosphory-
lation directly binds to the full-length BRCA1. In such an
Figure 3. A subset of cancer-predisposing
mutations in the COOH-terminal domain of 
BRCA1 cause increased chromatin unfolding. (A) 
Cancer-predisposing mutations were introduced 
into either the full-length BRCA1 (a–d) or AD2
(e–h). The corresponding expression vectors were 
transfected into AO3_1 cells, and immunostaining 
was performed as described in Fig. 1. (B) Summary 
of the effects of different cancer-associated mutations 
on chromatin unfolding. All mutants shown in this 
table were tested in the context of full-length 
BRCA1. Locations of missense mutations are
indicated by asterisks, whereas those of nonsense 
and frameshift mutations are indicated by wavy 
lines. All mutations are grouped into three (a–c) as 
discussed in the text. 
916 The Journal of Cell Biology 
 
|
 
 
 
Volume 155, Number 6, 2001
 
event, tethering lac–BRCA1 may simply bring the kinase(s)
to the tandem array of the lac binding sites, thus causing hy-
perphosphorylation of H2AX present in the surrounding
chromosomal region. Whereas the functional significance of
H2AX phosphorylation in chromatin unfolding remains to
be explored, our finding is consistent with the previous sug-
gestion of a physical link between 
 
 
 
-H2AX and BRCA1.
 
Allele-specific effects of cancer-predisposing mutations 
of BRCA1 on chromatin unfolding
 
To determine the effect of cancer-associated mutations on
the BRCA1-dependent chromatin unfolding, we introduced
a series of common cancer-predisposing mutations into ei-
ther full-length BRCA1 or AD2. Based on their behaviors in
the chromatin-unfolding assay, mutations were classified
into three phenotypic categories. The first includes nonsense
mutations resulting in truncation of the entire COOH ter-
minus (Fig. 3 B, a). According to previous studies, BRCA1
mutants that lack the COOH terminus of the protein are
defective in stimulating transcription and DNA repair (So-
masundaram et al., 1997; Abbott et al., 1999; Scully et al.,
1999; Jin et al., 2000). As shown in group a of Fig. 3 B,
these COOH-terminal truncation mutants also failed to in-
duce chromatin unfolding. The second group of mutants in-
clude missense mutations that are located upstream of AD2
(group b, i.e., C61G, S1040N, and R1347G). None of the
mutants in this group significantly affects BRCA1-mediated
chromatin unfolding.
Contrary to the behaviors of first two groups, mutations
in group c markedly enhanced the ability of lac-BRCA1
to induce chromatin unfolding (Fig. 3 B). For example,
A1708E, M1775R, and Y1853X led to a pronounced en-
largement of the unfolded chromatin structure (Fig. 3 A,
compare b with c and d, and e with f–h). The same muta-
tions also significantly increased the percentage of trans-
fected cells that showed chromatin unfolding (Fig. 3 B). For
instance, 79% of the cells that expressed the M1775R mu-
tant displayed significant chromatin unfolding, compared
with 14% for the wild-type full-length protein. This is an
even higher percentage than that previously observed for the
VP16 activator (Tumbar et al., 1999).
Interestingly, all mutations in group c result in single aa
substitutions or small deletions within the AD2 region.
Many of the mutations in this group have been shown previ-
ously to abolish AD2 interactions with other transcription-
related proteins, including the RNA pol II holoenzyme
(Scully et al., 1997a; Neish et al., 1998; Yarden and Brody,
1999). As discussed below, by retaining the chromatin un-
folding activity of BRCA1 but blocking its role in other
steps of transcriptional activation, these mutations in group
c may lead to accumulation of the highly decondensed chro-
matin structure as observed in the unfolding assay.
 
Identification of a novel BRCA1-interacting protein
 
Application of the chromatin unfolding assay allowed us to
identify a large-scale chromatin unfolding activity associated
with BRCA1, and to narrow down the chromatin-unfolding
region of BRCA1 to small subdomains in the COOH termi-
nus of the protein. To identify cofactors recruited by the
BRCT repeats to mediate chromatin unfolding, we used
BRCT1 as the bait in a yeast two-hybrid screen. One candi-
date gene, cofactor 
 
COBRA1
 
, was isolated from a human
ovary cDNA library. It encodes a novel 580-aa protein rich
in leucine residues (17%) (Fig. 4). COBRA1 also contains
three repeats of the LXXLL motif, often present in many
transcription coactivators and responsible for mediating
their ligand-dependent interactions with steroid hormone
receptors (Heery et al., 1997). Database searches revealed
COBRA1-related hypothetical proteins in mice and flies
that share 96 and 51% aa identity with the human protein,
respectively (Fig. 4).
To confirm the interaction between BRCA1 and
COBRA1, a lysate of human HEK293T cells that ectopi-
cally expressed FLAG-tagged COBRA1 was immunoprecip-
itated with an anti-FLAG antibody, followed by immuno-
blotting with an anti-BRCA1 antibody. As shown in Fig. 5
A, the endogenous human BRCA1 was coprecipitated in a
FLAG-COBRA1–dependent manner (lanes 1 and 2). As a
control, addition of an excess of FLAG peptide to the im-
munoprecipitation reaction abolished the BRCA1 signal in
the immunoprecipitate (Fig. 5 A, lane 3).
To further assess the binding specificity of COBRA1 to
the BRCT1 region of BRCA1, we cotransfected HEK293T
cells with FLAG-COBRA1 and lac repressor fused with var-
ious fragments of BRCA1. The cell lysates were then im-
munoprecipitated with the anti-FLAG antibody and sub-
sequently immunoblotted with the anti-lac antibody. As
shown in Fig. 5 B, lac-BRCT1 was capable of binding to the
FLAG-COBRA1 (lane 2). Consistent with their activity in
Figure 4. Sequence alignment of human COBRA1 and its
homologues from mice and flies. The conserved aa residues are 
highlighted in black, and the similar residues in gray. The locations 
of the LXXLL motif are indicated by asterisks. 
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chromatin unfolding, the COOH-, but not the NH
 
2
 
-termi-
nal half of BRCT1 (Fig. 1 B), interacted with COBRA1
(lanes 3 and 4). None of the BRCA1 fragments upstream
of the BRCT repeat, including AD1, displayed any signifi-
cant affinity for COBRA1 (lanes 5–8). Taken together, our
data show that the COBRA1 binding correlates with the
BRCT1-mediated large-scale chromatin unfolding.
As shown in Fig. 3, cancer-predisposing mutations in the
3
 
 
 
 region of 
 
BRCA1
 
 caused significant enhancement of the
chromatin unfolding activity. Intriguingly, the same muta-
tions (A1708E, M1775R, and Y1853X) also increased the af-
finity for COBRA1 in the coimmunoprecipitation assay (Fig.
5 B, compare lane 9 with lanes 10–12). A similar result was
also observed in an in vitro glutathione 
 
S
 
-transferase (GST)
pull-down assay (Fig. 5 C). In this case, 
 
35
 
S-labeled, in vitro–
translated COBRA1 was pulled down by both GST–AD and
GST–AD2, but not by GST–AD1 (Fig. 5 C, bottom panel,
lanes 3–5). Furthermore, COBRA1 displayed a higher affin-
ity for the mutant (M1775R) than the wild-type GST–AD2
fusion (Fig. 5 C, bottom panel, lanes 5 and 6). As a control,
we also used 
 
35
 
S-labeled CtIP, a transcriptional corepressor
that binds to the COOH terminus of BRCA1 (Wong et al.,
1998; Yu et al., 1998; Li et al., 1999). Consistent with previ-
ous findings, CtIP binds specifically to AD2 but, unlike
COBRA1, its association with AD2 is abolished by the
M1775R mutation (Fig. 5 C, top panel, lanes 5 and 6).
Thus, the same cancer-predisposing mutations exert opposite
effects on BRCA1 binding to two different partners.
 
Involvement of COBRA1 in BRCT1-mediated 
chromatin unfolding
 
To explore the role of COBRA1 in the BRCT1-mediated
chromatin unfolding, we cotransfected FLAG-COBRA1
with various lac–BRCA1 fusion constructs into AO3_1
cells. As detected by confocal immunofluorescent micros-
copy, FLAG-COBRA1 and lac–BRCT1 colocalized in 96%
of the cells that expressed both proteins (Fig. 6 A, a–c). In
contrast, we did not detect any enrichment of the FLAG-
COBRA1 signal at either the BRCT2- or AD1-unfolded
chromatin regions (Fig. 6 A, BRCT2, d–f, and AD1, g–i).
Thus, whereas all three subdomains are capable of inducing
large-scale chromatin unfolding, they appear to recruit dis-
tinct cofactors to mediate this process.
Wild-type AD2, which failed to induce chromatin un-
folding (Fig. 1), did not display any obvious colocalization
with COBRA1 (Fig. 6 A, panels j–l). However, two 3
 
 
 
 can-
cer-predisposing mutations in the same context led to pro-
nounced recruitment of COBRA1 to the unfolded chroma-
tin regions (Fig. 6 A, A1708E, m–o, and M1775R, p–r).
Colocalization of COBRA1 and the mutant lac–AD2 fusion
proteins was observed in 
 
 
 
90% cells that expressed both
proteins. Thus, the effect of the 3
 
 
 
 mutations on COBRA1
recruitment correlates with their stimulatory effects on chro-
matin unfolding.
To directly assess the impact of COBRA1 on large-scale
chromatin structure, we used lac repressor to target COBRA1
to the lac binding sites in AO3_1 cells. As shown in Fig. 6 B,
61% of the cells that expressed lac–COBRA1 showed a com-
parable extent of chromatin unfolding as did lac–BRCT1
Figure 5. Identification of COBRA1 as a novel BRCA1-interacting 
protein. (A). COBRA1 interacts with endogenous full-length 
BRCA1. Human HEK293T cells were transfected with either an 
empty vector (lane 1) or expression vector for the FLAG-tagged 
COBRA1 (F-COBRA1; lanes 2 and 3). Cell lysates were immuno-
precipitated (IP) with an anti-FLAG antibody conjugated to Protein A 
agarose beads (Sigma-Aldrich), in the absence (lane2) or presence 
(lane 3) of the FLAG peptide at a final concentration of 0.8  g/ml. 
The immunoprecipitates were immunoblotted (IB) with a 
monoclonal anti-BRCA1 antibody (AB1 from Oncogene), the
results of which are shown in the top panel. As controls, the 
crude lysates were immunoblotted for the endogenous BRCA1 
(middle) and the ectopically expressed FLAG-COBRA1 (bottom). 
(B) Further characterization of the interaction between BRCA1 
and COBRA1. Various lac–BRCA1 fusion constructs and the 
FLAG-COBRA1 expression vector were cotransfected into 
HEK293T cells. Cell lysates were immunoprecipitated with an 
anti-FLAG antibody and subsequently immunoblotted with an 
anti-lac antibody, the results of which are shown in the top 
panel. Expression of the lac fusion proteins was determined by 
immunoblotting of the crude lysates with the anti-lac antibody 
(bottom). (C) In vitro GST pull-down assay to characterize the 
BRCA1-COBRA1 interaction. Various GST fusion proteins were 
expressed in bacteria and coupled to glutathione agarose beads 
(unpublished data). An equal amount of the GST fusion proteins 
was used to pull down the 
35S labeled, in vitro translated CtIP 
(top) or COBRA1 (bottom). 
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(compare c and d with e and f). This finding strongly impli-
cates COBRA1 in BRCT1-mediated chromatin restructuring.
 
Discussion
 
Eukaryotic genomes are packaged through multiple steps
into higher levels of chromatin structure. It is now well es-
tablished that remodeling of local chromatin structure is a
key step common to the initiation of multiple chromosomal
functional events, including transcription, DNA replication,
repair, and recombination (Elgin and Workman, 2000; Fyo-
dorov and Kadonaga, 2001). Whereas intense research in
the past decade has provided a wealth of information regard-
ing the biochemical basis for chromatin remodeling at the
nucleosome level, much less is known about reorganization
of higher levels of chromatin structure. It remains unclear
whether the known modifications of nucleosome organiza-
tion are sufficient for changes in large-scale chromatin orga-
nization, or whether novel mechanisms acting at higher lev-
els of chromatin structure are responsible for changes in
large-scale chromatin organization.
A major difficulty in distinguishing these two possibilities
is that most assays for identifying transcriptional activators
or coactivators have used transcriptional activity as a final
readout. Direct assays for changes in higher order chromatin
structure have not been used previously. Because BRCA1
had been functionally implicated in a range of nuclear pro-
cesses, it was reasonable to postulate that the regulation of
these multiple nuclear events might occur through a general
chromatin remodeling activity of BRCA1. The lac repres-
sor–tethering system, while artificial in many aspects, pro-
vided an excellent assay to pursue this research direction.
Our findings in this current study strongly suggest that
BRCA1 recruits COBRA1, a novel factor, to the lac opera-
tor–containing chromatin region. Within the constraints of
the lac repressor–tethering assay, BRCA1-dependent un-
folding of higher levels of chromatin structure appears to be
at least partially mediated through recruitment of COBRA1.
Notably, BRCA1-mediated chromatin decondensation is
distinct from transcriptional activation per se and histone
hyperacetylation. It is unclear how unique the histone acety-
lation–independent chromatin unfolding is. Although the
chromatin unfolding produced by VP16, E2F1, and p53 is
accompanied by histone hyperacetylation, no causal rela-
tionship between histone acetyltransferases recruitment and
chromatin unfolding has been demonstrated. Moreover,
preliminary data suggests that large-scale decondensation
produced by estrogen receptor does not correlate with his-
tone hyperacetylation (A. Nye and A. Belmont, personal
communication).
Figure 6. COBRA1 colocalizes with lac–BRCT1 
and can induce large-scale chromatin unfolding. 
(A) Colocalization of lac fusion proteins (red) and 
FLAG-COBRA1 (green) at the unfolded chromatin 
region. AO3_1 cells were cotransfected with the 
expression vectors for FLAG-COBRA1 and
lac fused with various fragments of BRCA1.
The images were captured by confocal 
immunofluorescence microscopy. (B) COBRA1 
induces chromatin unfolding when directly targeted 
to the chromosome. AO3_1 cells were transfected 
with the expression vectors for lac repressor alone 
(a and b), lac–BRCT1 (c and d), or lac–COBRA1 
(e and f). Chromatin unfolding was detected as
described in the previous figures. 
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Whereas the lac-based chromatin-unfolding assay pro-
vides a new tool for visualizing chromatin dynamics and in
vivo protein–protein interactions in mammalian cells, it is
important to point out that the molecular and biochemical
basis for BRCA1-mediated chromatin decondensation is yet
to be understood. Furthermore, utilization of a long tandem
array of lac binding sites may raise the concern that the ob-
served chromatin unfolding could simply be due to steric ef-
fects of the proteins/protein complexes that are brought to
the lac binding sites. However, we believe this possibility is
unlikely because our work does not indicate an obvious cor-
relation between the potency of chromatin unfolding and
the size or charge of the tethered protein fragments. For ex-
ample, the minimal chromatin-unfolding domain defined in
our study is only 50 aa long (BRCA1C). In contrast, several
other BRCA1 fragments that range in size from 324 to 740
aa do not display any chromatin-unfolding activity (Fig. 1
B). In addition, BRCT1 and BRCT2 have a net charge of
 
 
 
5 and –6, respectively, yet both demonstrate strong chro-
matin-unfolding activity. On the other hand, BRCT1N car-
ries more positive charges (
 
 
 
5) than BRCT1C (
 
 
 
1), but
only the latter can induce chromatin decondensation. Fi-
nally, in previous work using either lac repressor tetramer, or
lac repressor fused to several other protein domains up to
 
 
 
350 aa in size (i.e., GFP), no effect on large-scale chroma-
tin structure has been observed (Robinett et al., 1996, and
A. Belmont, personal communication).
In our minds, a more serious caveat concerning the lac re-
pressor–tethering system is the question of whether the ob-
served effects produced by BRCA1 and other proteins on
large-scale chromatin unfolding are physiologically relevant
given the high numbers of lac operator repeats involved. In
fact, the exact number of lac repressors binding per lac oper-
ator has not been determined and there is reason to believe
that lac repressor binding may be significantly limited by
steric constraints and phasing of lac operators relative to the
nucleosome linker DNA. However, we note that a recent
study on a transgene array containing a viral promoter with
several glucocorticoid hormone response elements observed
a very similar type of large-scale chromatin decondensation
produced by glucocorticoid receptor (Muller et al., 2001).
Ultimately, validation of the physiological significance of
our observations of BRCA1-dependent large-scale chroma-
tin unfolding will depend on the outcome of future experi-
ments exploring the mechanisms of unfolding and identify-
ing the biological functions of other transacting factors
involved, such as COBRA1.
With these caveats in mind, we find it particularly intrigu-
ing that a subset of cancer-predisposing mutations of
BRCA1 lead to increased chromatin unfolding and recruit-
ment of COBRA1. Although the genotype–phenotype rela-
tionship in cancer-predisposing mutations of BRCA1 re-
mains to be understood, it is generally assumed that most, if
not all, BRCA1 mutations lead to loss of the biological func-
tions of the protein. However, the behaviors of the BRCA1
mutants in the chromatin-unfolding assay clearly demon-
strate an allele-specific effect. Consistent with this finding, it
has been reported that mutations at different locations along
the coding sequence of BRCA1 differentially affect the pene-
trance of BRCA1-dependent breast and ovarian cancer
(Gayther et al., 1995; Risch et al., 2001). It remains to be
determined whether the three groups of mutations that
cause differential effects on chromatin unfolding (Fig. 3)
may indeed lead to distinct clinical consequences in terms of
risks, types, or prognosis of BRCA1-associated cancers. In
particular, it will be interesting to see whether those 3
 
 
 
 mu-
tations that enhance chromatin unfolding exhibit any domi-
nant or semidominant phenotype in cancer genetics. It is
conceivable that constitutive decondensation of large-scale
chromatin structure may cause additional deleterious effects
on genome stability and thus result in more severe clinical
consequences in cancer development.
Our study also indicates that BRCT-mediated chromatin
unfolding may be tightly regulated. As shown in Figs. 1 and
3, a single BRCT motif is more potent in chromatin unfold-
ing than the larger fragments of the protein that contain
both BRCT repeats. Furthermore, the full-length wild-type
BRCA1 only exhibits a moderate chromatin-unfolding ac-
tivity, whereas the cancer-predisposing mutations in group c
(Fig. 3 B) that affect the integrity of the BRCT repeats sig-
nificantly enhance the chromatin-unfolding activity and
COBRA1 binding. These results lead us to the following
two models that could explain negative regulation of
BRCA1-mediated chromatin unfolding. In a “trans-inhibi-
tion” model, we speculate that binding of a putative inhibi-
tor (i.e., CtIP) to AD2 region of BRCA1 may prevent
BRCA1 from interacting with its cofactors for chromatin
unfolding (i.e., COBRA1). In an alternative, “cis-inhibi-
tion” model, the two BRCT tandem repeats may form an
intramolecular dimer. This in turn may reduce the affinity
of both BRCT repeats for their corresponding cofactors.
Conceivably, the “superactivating” mutations in group c
may prevent binding of the putative inhibitor or the intra-
molecular interaction between the two BRCT motifs, thus
rendering the protein constitutively active for binding to the
cofactors that mediate chromatin unfolding.
It is plausible that BRCT-mediated chromatin unfolding
may lead to a novel nuclear function of BRCA1 in global re-
organization of the genome. However, in light of the known
function of the COOH-terminal region of BRCA1 in tran-
scription and DNA repair, the observed chromatin decon-
densation may represent the first step in BRCA1-mediated
regulation of these two nuclear processes (Fig. 7). In such a
Figure 7. Model for BRCA1-mediated nuclear functions. Inhibitory 
and stimulatory effects of the 5  and 3  mutations on the three steps 
are indicated by bars and arrows on the sides, respectively. Factors 
in parentheses are those that may be targeted or recruited by BRCA1 
to facilitate a specific step in activation of transcription or DNA
repair. See text for more detail. 
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model, higher order chromatin decondensation may be fol-
lowed by BRCA1-mediated chromatin modification at the
nucleosomal level (i.e., histone hyperacetylation) and re-
cruitment of the transcription or repair machineries. As
shown in Fig. 7, nonsense mutations that result in trunca-
tion of the entire COOH-terminal region (5
 
 
 
 mutations)
may abolish BRCA1 functions in all three steps, resulting in
a completely inactive mutant protein. On the other hand,
mutations located at the 3
 
 
 
 end of the gene (3
 
 
 
 mutations)
may render BRCA1 incompetent at the second and third
steps, but still allow constitutive chromatin decondensation
at the first step. This could then lead to accumulation of ex-
tensively unfolded chromatin structure as seen in our study.
Consistent with this model, many 3
 
 
 
 cancer-predisposing
mutations abolish BRCA1 interactions with RNA pol II ho-
loenzyme and the histone modifying enzymes (Scully et al.,
1997a; Neish et al., 1998; Yarden and Brody, 1999), as well
as nucleosome remodeling in yeast (Hu et al., 1999). Thus,
chromatin unfolding may be a necessary but not sufficient
step for BRCA1-dependent transcriptional activation. Addi-
tional steps such as histone modification and recruitment of
the basal machinery may also be required for fulfilling
BRCA1 function in transcription and DNA repair.
 
Materials and methods
 
Chromatin unfolding assay
 
To construct the EGFP-lac-E2F1 and EGFP-lac-p53 fusion expression vec-
tors, the PCR fragments that encode the E2F1 (aa 368–437) and p53 (aa
1–73), respectively, were cloned into the AscI site in the plasmid p3
 
 
 
SS d
tb Cl EGFP AscI (NYE4) (A.C. Nye and A.S. Belmont, personal communica-
tion). The correct orientation of the inserts was identified by colony hybrid-
ization and confirmed by DNA sequencing. To construct the lac-BRCA1
plasmids, the sequence for lac repressor was first amplified by PCR from
the plasmid NYE4. The lac sequence was cloned into the HindIII–NotI sites
of pRC-CMV (Invitrogen), generating pRC-lac. Various BRCA1 fragments
and the COBRA1 sequence were amplified by PCR and inserted into the
unique AscI site of pRC-lac.
The chromatin unfolding experiments were performed as previously de-
scribed (Tumbar et al., 1999). Briefly, AO3_1 cells were transiently transfected
with the lac expression vectors using the FuGENE 6 transfection reagent
(Roche). The medium was changed 24 h after transfection and cells were im-
munostained 48 h after transfection. Cells grown on glass coverslips were
fixed with 1.6% paraformaldehyde for 30 min in PBS, permeabilized with
0.2% Triton X-100 in PBS for 5 min, and blocked in 1% normal goat serum in
PBS for 1 h. The coverslips were then incubated with primary antibodies at
room temperature for 1 h, followed by incubation with the appropriate sec-
ondary antibodies for 1 h. Unless otherwise specified, a rabbit polyclonal
anti–lac repressor antibody (Stratagene) and mouse monoclonal anti-FLAG an-
tibody (Sigma-Aldrich) were applied at 1:20,000 dilution. The anti–acetylated
histone H3 antibody was raised against di-acetylated H3 (Lys9 and Lys14)
(Boggs et al., 1996) (Lin et al., 1989), a gift from Drs. C. Mizzen and C.D. Allis
(University of Virginia, Charlottesville, VA). The secondary antibodies were
goat anti–rabbit IgG-conjugated with Cy3 (Amersham), and horse anti–mouse
IgG-conjugated with fluorescein isothiocyanate (FITC; Vector Laboratories).
For visualization of the nuclei, cells were stained with 0.2 
 
 
 
g/ml 4,6-
diamidino-2-phenylindole (DAPI) for 5 min before mounting. Fluorescent
images were acquired by a charged-coupled device camera (Hamamatsu
ORCA) that was mounted on a Nikon Microphot-SA microscope and
equipped with Improvision Openlab software. Confocal images were col-
lected on a Zeiss LSM410 confocal microscope. Figs. were assembled us-
ing Adobe Photoshop (v. 5.5).
 
Yeast two-hybrid screen
 
To identify proteins that specifically interact with the BRCT1 repeat of
BRCA1, the standard yeast two-hybrid screen was performed in the follow-
ing manner. First, the bait plasmid was generated by inserting a PCR-ampli-
fied cDNA fragment encoding the BRCT1 sequence (aa 1642–1736) into the
NdeI–EcoRI restriction sites of pAS2–1 (CLONTECH Laboratories, Inc.), re-
 
sulting in an in-frame fusion with the GAL4 DNA-binding domain. The re-
sultant plasmid, pAS2-BRCT1, and a human ovary cDNA prey library
(CLONTECH Laboratories, Inc.) were sequentially transformed into the 
 
S.
cerevisiae
 
 strain CG1945 according to the manufacturer’s instructions
(CLONTECH Laboratories, Inc.). Transformants were plated on synthetic
medium lacking tryptophan, leucine and histidine but containing 1 mM
3-aminotriazole. Approximately 2.3 million transformants were screened.
The candidate clones were retrieved from the yeast cells and reintroduced
back to the same yeast strain to verify the interaction between the candidates
and the BRCT1 bait. The specificity of the interaction was determined by com-
paring the interactions between the candidates and various bait constructs.
 
Coimmunoprecipitation
 
HEK293T cells were transfected using LipofectAmine 2000 (GIBCO BRL).
24 h after transfection, cells were washed twice with PBS and lysed in 0.5
ml lysis buffer (50 mM Hepes, pH 8, 250 mM NaCl, 0.1% NP-40, and pro-
tease inhibitor tablets from Roche). After brief sonication, the lysate was
centrifuged at 16,000 
 
g
 
 for 12 min at 4
 
 
 
C. The supernatant was used for
subsequent coimmunoprecipitation. 20 
 
 
 
l of the supernatant was used as
crude extract for detecting protein expression level. 15 
 
 
 
l of a 50% slurry
of the anti-FLAG agarose beads (Sigma-Aldrich) was used in each immu-
noprecipitation. Immunoprecipitation was performed overnight at 4
 
 
 
C.
The beads were centrifuged at 3,300 rpm for 2 min, and washed three
times with washing buffer (50 mM Hepes, pH8, 500 mM NaCl, 0.5% NP-
40) and three times with RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl,
1% NP-40, 0.1% SDS, and 0.5% sodium deoxycholate). Each wash was
performed for at least 30 min. The precipitates were then eluted in 15 
 
 
 
l
2
 
 
 
 SDS-PAGE sample buffer. Gel electrophoresis was followed by immu-
noblotting according to standard procedures.
 
GST pulldown assay
 
The PCR fragments encoding various BRCA1 fragments were cloned into
pGEX-2T and the constructs were confirmed by sequencing. The GST-BRCA1
proteins were made and purified, with the induction of protein expression per-
formed at 19
 
 
 
C overnight. pcDNA3 vector containing the COBRA1 gene was
used for in vitro transcription and translation in the TnT Reticulocyte Lysate
system (Promega). The 
 
35
 
S-labeled COBRA1 was translated in vitro according
to the manufacturer’s instructions and mixed with 10 
 
 
 
g the GST-bound bead
in 0.5 ml binding buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 0.3 mM DTT, 0.1% NP-40 and protease inhibitor tablet). The binding
reaction was performed at 4
 
 
 
C overnight and the beads were subsequently
washed four times with washing buffer (same as binding buffer except 0.5%
NP-40 was used), 30 min each time. The beads were eluted in 10 
 
 
 
l 2 
 
 
 
 SDS-
PAGE sample buffer and the proteins were resolved on 10% denaturing gel.
The gel was then dried and exposed to x-ray films for overnight.
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